title: Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.
abstract: BACKGROUND
  Bosentan (an oral dual endothelin receptor antagonist) improves symptoms and cardiac hemodynamics and reduces clinical worsening in patients with pulmonary arterial hypertension (PAH). The VITAL study assessed the effect of bosentan on quality of life in patients with WHO Functional Class III or IV PAH (idiopathic or associated with connective tissue diseases).
  
  
  METHODS
  Quality of life was assessed prospectively using the MOS SF-36 and AQOL questionnaires. Baseline readings and scores at 3 and 6 months were collected, in addition to other efficacy and safety data.
  
  
  RESULTS
  Among the 177 study patients, SF-36 scores were significantly improved at 3 months in the domains of physical functioning (27.3 to 34.8; p < 0.0001), role-physical (16.6 to 30.9; p < 0.0001), vitality (35.2 to 41.1; p = 0.0003), social functioning (48.0 to 58.6; p < 0.0001), mental health (64.2 to 72.0; p = 0.005) and role-emotional (44.8 to 58.1; p = 0.001). Improvements were seen in all etiologic sub-groups and were maintained in patients who remained on bosentan. An improvement in AQOL measures at 3 months was also noted for patients with baseline WHO Functional Class III.
  
  
  CONCLUSIONS
  Bosentan significantly improves quality of life in patients with idiopathic PAH or PAH associated with connective tissue diseases.
authors.affiliation: Victor Chang Research Institute, St. Vincent's Hospital, Sydney, Australia. amkeogh@stvincents.com.au <amkeogh@stvincents.com.au>
authors.forename: Anne M
authors.initials: AM
authors.lastname: Keogh
authors.forename: Keith D
authors.initials: KD
authors.lastname: McNeil
authors.forename: John
authors.initials: J
authors.lastname: Wlodarczyk
authors.forename: Eli
authors.initials: E
authors.lastname: Gabbay
authors.forename: Trevor J
authors.initials: TJ
authors.lastname: Williams
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan